Pyxis Oncology Inc PYXS.OQ PYXS.O is expected to show a fall in quarterly revenue when it reports results on May 12 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Pyxis Oncology Inc is for a loss of 29 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Pyxis Oncology Inc is $6.00, above its last closing price of $1.09.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.34 | -0.33 | -0.25 | Beat | 24.2 |
Sep. 30 2024 | -0.31 | -0.31 | -0.35 | Missed | -11.7 |
Jun. 30 2024 | -0.32 | -0.32 | -0.29 | Beat | 10.6 |
Mar. 31 2024 | -0.21 | -0.24 | -0.06 | Beat | 75.2 |
Dec. 31 2023 | -0.48 | -0.47 | -0.33 | Beat | 30.5 |
Sep. 30 2023 | -0.49 | -0.51 | -0.56 | Missed | -10.5 |
Jun. 30 2023 | -0.64 | -0.65 | -0.41 | Beat | 36.7 |
Mar. 31 2023 | -0.90 | -0.90 | -0.55 | Beat | 38.8 |
This summary was machine generated May 9 at 15:13 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。